Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.
The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).
The acquisition adds an investigational small molecule that targets and degrades the MLLT1 (ENL) and MLLT3 (AF9) proteins.
These proteins are "histone readers" that serve as master regulators for the Super Elongation Complex (SEC), a transcriptional engine that cancers often "hijack" to drive the expression of powerful oncogenes like MYC and HOXA9.
By using a degrader rather than a traditional inhibitor, the therapy physically eliminates the MLLT1/3 proteins, leading to a collapse of the SEC and the death of leukemia cells.